Search Results
Sep 02, 2026, 09:09 ET /C O R R E C T I O N -- Jarrow Formulas/
Jarrow Formulas® for more information.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.Media Contact: Ciana Williams |
More news about: Jarrow Formulas
Sep 02, 2026, 09:05 ET 20 Years Advancing NICU Nutrition and Improving Outcomes for Babies Under 3 Pounds
worldwide have benefited from Prolacta's human milk-based fortifiers and formulas since 2006.3 In a global first, Japan granted prescription drug status to Prolacta's PreemieFort® fortifiers in late 2025 for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital
More news about: Prolacta Bioscience
Sep 02, 2026, 09:00 ET CMC Bottleneck is Choking Biopharma's Drug Pipeline, says Zifo
multimedia:https://www.prnewswire.com/news-releases/cmc-bottleneck-is-choking-biopharmas-drug-pipeline-says-zifo-302867680.htmlSOURCE
More news about: Zifo
Sep 02, 2026, 09:00 ET RazorMetrics Provider Network Expands to Nearly 1.7 Million Prescribers Nationwide
New York lead the network by prescriber count."Supporting prescribers within the workflows they already use is essential to reducing avoidable drug spend," said Siva Mohan, MD, co-founder, president, and chief medical officer of RazorMetrics. "That breadth allows us to deliver lower-cost, clinically
More news about: RazorMetrics
Sep 02, 2026, 09:00 ET BioMarin to Participate in Upcoming Investor Conferences
a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound
More news about: BioMarin Pharmaceutical Inc.
Sep 02, 2026, 09:00 ET Charlene Son Rigby of Global Genes Recognized as a 2026 Fierce 50 Honoree
Recognition highlights Global Genes' work building the infrastructure that puts rare disease patient advocates at the center of drug developmentWASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Global Genes today announced
More news about: RARE-X
Sep 02, 2026, 09:00 ET AHA/ASA 2026 Guideline Now Recognizes Pharyngeal Electrical Stimulation for Stroke Rehabilitation
sensory nerves in the pharynx and is used in addition to standard dysphagia care. In the United States, the Phagenyx System is cleared by the Food and Drug Administration (FDA) as an aid to improve swallowing in patients with severe dysphagia post-stroke.
More news about: Phagenesis
Sep 02, 2026, 08:49 ET FDA Allows First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease
The Mucolipidosis Type IV (ML4) Foundation announces that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug (IND) application to proceed for the first-ever U.S. clinical trial of an experimental gene therapy for Mucolipidosis
More news about: The Mucolipidosis Type IV (ML4) Foundation
Sep 02, 2026, 08:30 ET New HCPCS Billing Code Enables Medicare Benefit Billing of Lasix® ONYU When Furnished Incident to a Physician's Service
the exact scenario for which we developed this product." About Lasix ONYU Lasix® ONYU is a drug-device combination that was approved by the U.S. Food and Drug Administration on October 7, 2025, for the treatment of edema in adult patients with chronic heart failure. Lasix ONYU
More news about: SQ Innovation
Sep 02, 2026, 08:30 ET Halozyme to Participate at Upcoming Investor Conferences
company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected
More news about: Halozyme Therapeutics, Inc.
Sep 02, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for September 2026
Upcoming free, educational webinars from Xtalks will cover topics in clinical trials, commercialization and HEOR, drug safety, laboratory technology, patient recruitment and retention, pharma manufacturing and supply chain and preclinical research.TORONTO,
More news about: Xtalks
Sep 02, 2026, 08:30 ET Unisys Research on Trustworthy AI Published in Frontiers in Pharmacology Journal
From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing," in Frontiers in Pharmacology, a leading journal from
More news about: Unisys Corporation
Sep 02, 2026, 08:30 ET The Rise of Physician Supergroups: How Life Science Companies Can Reach These Emerging Mega-practices, Upcoming Webinar Hosted by Xtalks
value-based care and vertical integration in accelerating this trend.Attendees will learn how physician supergroups are reshaping market access, drug utilization and relationships across the healthcare ecosystem, as well as strategies for effectively engaging these organizations and optimizing product
More news about: Xtalks
Sep 02, 2026, 08:30 ET Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
More news about: Caris Life Sciences
Sep 02, 2026, 08:00 ET Atrium Therapeutics to Participate in Upcoming Investor Conferences
Since its launch earlier this year, Atrium has made meaningful progress including U.S. Food and Drug Administration (FDA) clearance of the Company's Investigational New Drug (IND) application for ATR-1072 for the treatment of PRKAG2 syndrome, receipt of a No Objection Letter from Health
More news about: Atrium Therapeutics
Sep 02, 2026, 08:00 ET Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:Cantor Global Healthcare
More news about: Whitehawk Therapeutics, Inc.
Sep 02, 2026, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
innovative therapies for serious cardiovascular and cardiometabolic diseases. Leveraging its expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy and heart failure.
More news about: Edgewise Therapeutics
Sep 02, 2026, 08:00 ET Hamamatsu Receives FDA 510(k) Clearance for NanoZoomer S20MD and S540MD Slide scanner systems
Sept. 2, 2026 /PRNewswire/ -- Hamamatsu Photonics K.K. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the NanoZoomer S20MD and NanoZoomer S540MD Slide scanner systems. Building on the previously cleared NanoZoomer S360MD, these
More news about: Hamamatsu Photonics K.K.
Sep 02, 2026, 08:00 ET The Michael J. Fox Foundation Releases "So Your Friend Has Parkinson's" Awareness Campaign for Parkinson's Research
breakthroughs. Since its launch in 2000, the Foundation has relentlessly focused on galvanizing philanthropic resources to transform the state of Parkinson's drug development, helping drive the field to this moment of tremendous promise. The campaign leverages this momentum in advance of the public launch of MJFF's
More news about: The Michael J. Fox Foundation for Parkinson's Research
Sep 02, 2026, 07:30 ET Rapafusyn Pharmaceuticals to Present at the H.C. Wainwright 28th Annual Global Investment Conference
transcription factors, transmembrane receptors, transporters/SLCs, enzymes and ligases. RapaGlues™ have produced innovative drug candidates for broad types of challenging drug targets, and frequently exhibit cell permeability directly from the starting point, enhancing their potential for therapeutic
More news about: Rapafusyn Pharmaceuticals
Sep 02, 2026, 07:28 ET CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
hospital stays, and higher costs, creating a significant unmet clinical need. Historically, surgeries were delayed by three to seven days to allow the drug to be naturally eliminated, thereby reducing bleeding risk. Today, CytoSorb represents a much more attractive alternative as the only specifically approved
More news about: CytoSorbents Corporation
Sep 02, 2026, 07:15 ET Transpire Bio to Participate in Upcoming Healthcare Investor Conferences During September
Bio Inc. is an integrated, US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio harnesses its inhaled drug delivery expertise to improve patients' lives by expanding access to important therapies and developing treatments for serious diseases where therapeutic
More news about: Transpire Bio
Sep 02, 2026, 07:00 ET Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
endpoint, delivering positive topline results and a decisive statistical margin over placebo. Based on these results, Raziel and Fosun plan to submit a New Drug Application (NDA) for RZL-012 in China by the end of 2026.Efficacy was assessed 84 days after a single treatment cycle. Looking beyond submental
More news about: Raziel Therapeutics; Fosun Pharma
Sep 02, 2026, 07:00 ET Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
AlteogenAlteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs,
More news about: Alteogen Inc.
Sep 02, 2026, 06:30 ET Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of
More news about: Immunic, Inc.